{
    "nctId": "NCT00542191",
    "briefTitle": "Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer",
    "officialTitle": "Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "1) Pathologic Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with Estrogen Receptor (ER), Progesterone Receptor (PR),and HER2 negative invasive breast cancer confirmed on core biopsy.(Note: HER2 negative by FISH preferred; HER2 0 or 1+ by IHC acceptable)\n* Primary tumor size 2cm or greater by physical exam or radiographic measurements.(Note: Locally advanced T4 or inflammatory breast cancer is eligible.)\n* Assessment of pre-treatment axillary lymph nodal status (Note: FNA biopsy if palpable or sentinel lymph node biopsy (SLNB) if not palpable preferred; clinical exam acceptable.)\n* Absolute neutrophil count \\> 1500 mm3 and platelet count \\> 100,000 mm3\n* Normal myocardial left ventricular function\n* Serum creatinine \\< 2.0 mg/dl\n* Total bilirubin and AST \\< 3X upper limits normal\n\nExclusion Criteria:\n\n* Recurrent or metastatic breast cancer findings (Note: If oncologically felt to be a second breast primary, patient eligible for this protocol)\n* Another active cancer present\n* Medical contraindications to chemotherapy or surgery\n* First trimester pregnancy\n* Breast feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}